Kevin DeGeeter
Stock Analyst at Oppenheimer
(1.71)
# 2,193
Out of 4,479 analysts
30
Total ratings
31.43%
Success rate
44.36%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $2.13 | +932.86% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $7.52 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $1.20 | +1,900.00% | 3 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $16.80 | +483.33% | 1 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $19.98 | +525.63% | 2 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | n/a | $2.27 | - | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | n/a | $5.59 | - | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $1.31 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | n/a | $0.18 | - | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | n/a | $340.44 | - | 1 | Aug 24, 2021 | |
| EXAS Exact Sciences | Maintains: Outperform | n/a | $43.17 | - | 1 | Jul 29, 2021 | |
| SNSE Sensei Biotherapeutics | Downgrades: Perform | n/a | $0.63 | - | 2 | Jun 29, 2021 | |
| RZLT Rezolute | Initiates: Outperform | n/a | $4.21 | - | 1 | May 27, 2021 | |
| CYCC Cyclacel Pharmaceuticals | Initiates: Outperform | $255 | $1.66 | +15,261.45% | 1 | Apr 30, 2021 | |
| EVAX Evaxion Biotech | Initiates: Outperform | $180 | $2.90 | +6,117.62% | 1 | Mar 2, 2021 | |
| VCEL Vericel | Downgrades: Perform | n/a | $45.07 | - | 1 | Jan 11, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | n/a | $2.16 | - | 1 | Jan 5, 2021 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Perform | n/a | $19.78 | - | 1 | Dec 8, 2020 | |
| CLRB Cellectar Biosciences | Initiates: Outperform | n/a | $2.38 | - | 1 | Jul 1, 2020 | |
| BNGO Bionano Genomics | Initiates: Outperform | n/a | $0.57 | - | 1 | Apr 8, 2020 | |
| IDXG Interpace Biosciences | Maintains: Outperform | n/a | $1.10 | - | 1 | Jan 16, 2020 | |
| NVAX Novavax | Upgrades: Buy | n/a | $12.97 | - | 1 | Aug 9, 2017 | |
| MTEM Molecular Templates | Initiates: Buy | n/a | $1.16 | - | 1 | Aug 3, 2017 | |
| CDTX Cidara Therapeutics | Initiates: Buy | $225 | $11.93 | +1,786.00% | 1 | Apr 12, 2017 | |
| MYGN Myriad Genetics | Upgrades: Neutral | n/a | $24.76 | - | 1 | Feb 8, 2017 | |
| CDXS Codexis | Upgrades: Buy | n/a | $2.89 | - | 1 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $2.13
Upside: +932.86%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.52
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $1.20
Upside: +1,900.00%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $16.80
Upside: +483.33%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $19.98
Upside: +525.63%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.27
Upside: -
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.59
Upside: -
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $1.31
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.18
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: n/a
Current: $340.44
Upside: -
Exact Sciences
Jul 29, 2021
Maintains: Outperform
Price Target: n/a
Current: $43.17
Upside: -
Sensei Biotherapeutics
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.63
Upside: -
Rezolute
May 27, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.21
Upside: -
Cyclacel Pharmaceuticals
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $1.66
Upside: +15,261.45%
Evaxion Biotech
Mar 2, 2021
Initiates: Outperform
Price Target: $180
Current: $2.90
Upside: +6,117.62%
Vericel
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $45.07
Upside: -
Taysha Gene Therapies
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.16
Upside: -
Rocket Pharmaceuticals
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $19.78
Upside: -
Cellectar Biosciences
Jul 1, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.38
Upside: -
Bionano Genomics
Apr 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.57
Upside: -
Interpace Biosciences
Jan 16, 2020
Maintains: Outperform
Price Target: n/a
Current: $1.10
Upside: -
Novavax
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $12.97
Upside: -
Molecular Templates
Aug 3, 2017
Initiates: Buy
Price Target: n/a
Current: $1.16
Upside: -
Cidara Therapeutics
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $11.93
Upside: +1,786.00%
Myriad Genetics
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $24.76
Upside: -
Codexis
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.89
Upside: -